MannKind Analyst Turns Bullish, Says 'Don't Call It Comeback'
Portfolio Pulse from Priya Nigam
Wedbush analyst Andreas Argyrides has initiated coverage of MannKind Corp (NASDAQ:MNKD) with an Outperform rating and a price target of $10. Argyrides praised MannKind's turnaround from bankruptcy and its commitment to innovation. He highlighted the strong launch of Tyvaso DPI and the strategic development in pulmonary fibrosis with MNKD-201 (nintedanib) and MNKD-501. Shares of MannKind had risen by 2.73% to $3.05 at the time of publication.
October 10, 2023 | 4:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides has initiated coverage of MannKind Corp with an Outperform rating and a price target of $10. This positive outlook could potentially drive the stock price up in the short term.
The initiation of coverage by a well-known analyst like Andreas Argyrides with a positive rating and a price target significantly higher than the current price can be a strong positive signal to the market. This can lead to increased buying pressure, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100